# NAD+ FAQ: Clinical Questions, Side Effects, Dosage, and Regulation Answered

> NAD+ frequently asked questions — IV therapy, injection, dosage, side effects, NMN vs NR, FDA status, and more. Direct answers from the clinical literature.

## NAD+ Side Effects Reported in Clinical Literature

Side-effect profiles differ substantially by route:

**Intravenous NAD+:** Flushing, chest tightness/pressure, nausea, elevated heart rate, muscle cramping. Rate-dependent: managed by slowing infusion to ≤2 mg/min. IV NAD+ (500 mg) caused moderate-to-severe GI symptoms requiring mean 97-minute infusion; IV NR (500 mg) caused only mild tingling and took 37 minutes on average [10]. All symptoms resolved post-infusion.

**Oral NMN:** Single doses of 100–500 mg safe with no adverse effects [3]. Daily supplementation at 250–900 mg/day for 8–12 weeks shows no safety signals [4, 5, 6, 7].

**Oral NR:** Well-tolerated at doses up to 3000 mg/day in the NR-SAFE Parkinson trial [18]. No flushing at any dose.

## What does NAD+ do for the body?

NAD+ is a coenzyme present in every living cell, essential for ATP production via the mitochondrial electron transport chain, sirtuin-mediated gene regulation and mitochondrial biogenesis, and PARP1-dependent DNA repair. Blood and tissue levels decline approximately 50% between young adulthood and age 60 [22].

## What is the downside of NAD+?

Common reactions during IV infusion include flushing, nausea, and chest tightness — managed by slowing the infusion rate. Oral precursors NMN and NR are generally very well tolerated. Long-term safety data beyond 12 weeks remains sparse. Theoretical concern: NAD+ supports cancer cell proliferation pathways; no increase in cancer incidence observed in published human trials.

## Is NAD+ just vitamin B3?

No. Niacin (vitamin B3) is one biosynthetic precursor to NAD+ via the Preiss-Handler pathway, but NAD+ is a dinucleotide coenzyme — structurally and pharmacologically distinct — with molecular weight 663.4 Da (vs 123.1 Da for niacin).

## What is IV NAD therapy?

Intravenous infusion of pharmaceutical-grade NAD+ solution directly into the bloodstream, bypassing gut degradation. Plasma NAD+ and metabolites elevated substantially throughout and detectable in urine post-infusion (Grant et al. 2019, 750 mg over 6 hours) [9]. Not FDA-approved for any indication.

## Does NAD+ IV therapy actually work?

IV NAD+ consistently elevates plasma NAD+ during infusion — confirmed [9]. For clinical endpoints: a 50-case series in substance use disorder showed statistically significant reductions in craving, anxiety, and depression [11]; historical addiction case series reported craving and withdrawal symptom removal [12]. Large controlled RCTs have not been published as of 2026 [19].

## What is an NAD+ injection?

Subcutaneous (SC) or intramuscular (IM) administration of compounded NAD+ solution. Bypasses gut degradation while requiring less clinical infrastructure than IV infusion. Practitioner protocols: 100–500 mg SC/IM, 1–3 times weekly. Active registered clinical trials underway as of 2026; no completed published RCT yet available.

## Which is better for increasing NAD+, NR or NMN?

Both raise blood NAD+ approximately 2-fold over placebo in a direct comparison RCT (Christen et al. 2026, Nature Metabolism; ~49 µM for NR and ~43 µM for NMN, both p<0.001; NAM ineffective) [16]. NR remains a legal dietary supplement; NMN was classified as a drug ingredient by FDA in January 2023.

## Is NAD+ IV therapy safe?

Favorable safety profile when infusion rates are properly controlled (≤2 mg/min). Adverse reactions are rate-dependent and resolve upon slowing or stopping the infusion. No serious adverse events documented in published trial and case-series record as of 2025 [9, 10, 11].

## Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme with molecular formula C₂₁H₂₇N₇O₁₄P₂ and molecular weight 663.4 Da. It is not a peptide, not an amino acid derivative, and has no structural or pharmacological relationship to peptide research compounds or GLP-1 agonist drugs.

## FDA regulatory status of NMN and NAD+ precursors

FDA excluded NMN from the dietary supplement category in January 2023 after ChromaDex filed an IND application. This affects retail supplement sales in the US but does not restrict licensed practitioners from using compounded NAD+ or NMN in clinical settings. NR remains a legal dietary supplement under DSHEA.

---

Chrome-console readings of the peer-reviewed NAD+ record — clinical trials indexed, infusion rates logged, no prescriptions filled.